Durvalumab vs Rituximab

Durvalumab vs Rituximab: Overview

This comparison examines the pharmacological differences between Durvalumab and Rituximab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Rituximab — 22 days.

Chemical Properties

Type: Durvalumab — Antibody; Rituximab — Antibody.